Drugs / AZD3043
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01086813 | Mar → Apr 2010 | — | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 1 | NCT01028040 | Dec 2009 → Aug 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00984880 | Sep → Dec 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00918515 | May → Aug 2009 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD3043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00984880 ↗ |
| Known as | THRX-918661 | “AZD3043 (THRX-918661) is an investigational phenylpropanoid sedative/anesthetic that is rapidly metabolized by esterases in blood and liver.” PMID 26097986 ↗ Oct 2015 |
| Modality | Small molecule | — CHEMBL3354350 ↗ |
| Route | Intravenous | “intravenous solution given once as intravenous infusion over 30 minutes” NCT00918515 ↗ |